EU adds severe allergies as side effect of Novavax COVID vaccine

The European Medicines Agency on Thursday identified severe allergic reactions as potential side effects of Novavax Inc's (NVAX.O) COVID-19 vaccine. The vaccine was authorized by U.S. regulators on Wednesday, and its product label in the United States warns against administering the shot to people with a history of allergic reactions to any components of the shot. Shares of Novavax fell 20.3% to $55.72 in morning trading, along with the broader market and other COVID-19 vaccine makers. Novavax shares are usually volatile.